SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (833)2/3/1999 9:42:00 AM
From: Larry Liebman  Respond to of 3202
 
A extraordinarily bullish report by the C.E.O. It will be interesting to see how the analyst's interpret the data. Let Celera have AMGN, while INCY has big pharma. Yes, I'll recommend INCY!



To: LLCF who wrote (833)2/3/1999 1:46:00 PM
From: Rocketman  Read Replies (1) | Respond to of 3202
 
Just to show how imbalanced market cap valuations can be, AFFX which is basically equivalent to the Synteni portion of INCY has an $890M market cap, while INCY has one of only $760M. Now THAT is an imbalance in valuations!!!

Rman


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News